Psoriasis and Malignancy
Canadian Dermatology Today · 20.03.2026 · 5-9
DOI: 10.58931/cdt.2026.71156 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Dermatology Today, online erschienen am 20.03.2026. Verfasst von Ron Vender.
Abstract (Originalsprache)
KEY TAKEAWAYS: • Psoriasis confers a modest overall increase in malignancy risk, concentrated in NMSC and selected lymphoid cancers, and amplified by disease severity and cumulative PUVA/systemic exposure. • Chronic systemic inflammation and, in some contexts, therapy-related immunomodulation jointly shape cancer risk in psoriasis, rather than biologic treatment being uniformly carcinogenic. • Modern biologic and targeted therapies—including IL-17 and IL-23 inhibitors, as well as PDE4 and TYK2 inhibitors—generally show no clear increase in overall malignancy or recurrence risk, though ongoing pharmacovigilance and individualized oncology input remain crucial. • Management should be multidisciplinary and risk-adapted, combining effective psoriasis control with tailored cancer surveillance and aggressive modification of lifestyle risk factors (smoking, alcohol, obesity, UV exposure).
Zitieren
APA
Vender, R. (2026). Psoriasis and Malignancy. Canadian Dermatology Today, 5-9. https://doi.org/10.58931/cdt.2026.71156
Vancouver
Vender R. Psoriasis and Malignancy. Canadian Dermatology Today. 2026:5-9. doi:10.58931/cdt.2026.71156
BibTeX
@article{Vender2026,
author = {Vender, Ron},
title = {Psoriasis and Malignancy},
journal = {Canadian Dermatology Today},
year = {2026},
pages = {5--9},
doi = {10.58931/cdt.2026.71156}
}
EUVIMED